Efficacy of combined use of anti-VEGF (Aflibercept) and lasercoagulation for corneal neovascularisation before keratoplasty
暂无分享,去创建一个
[1] С. В. Труфанов,et al. РЕАКЦИЯ ТКАНЕВОЙ НЕСОВМЕСТИМОСТИ ПОСЛЕ ТРАНСПЛАНТАЦИИ РОГОВИЦЫ , 2017 .
[2] Александр Алексеевич Федоров,et al. Экспериментально-морфологическое исследование влияния антиангиогенной терапии на новообразованные сосуды роговицы , 2013 .
[3] R. Dana,et al. Topical Ranibizumab as a Treatment of Corneal Neovascularization , 2013, Cornea.
[4] S. Tuft,et al. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial , 2012, British Journal of Ophthalmology.
[5] R. Dana,et al. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). , 2012, The ocular surface.
[6] D. Azar,et al. Hemangiogenesis and Lymphangiogenesis in Corneal Pathology , 2012, Cornea.
[7] Claus Cursiefen,et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.
[8] A. Rouvas,et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. , 2008, American journal of ophthalmology.
[9] Claus Cursiefen,et al. Immune privilege and angiogenic privilege of the cornea. , 2007, Chemical immunology and allergy.
[10] J. Niederkorn. The immune privilege of corneal allografts. , 1999, Transplantation.
[11] V. Nirankari,et al. Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty. , 1986, Ophthalmology.
[12] L. Dandona,et al. Laser photocoagulation of experimental corneal stromal vascularization. Efficacy and histopathology. , 1993, Ophthalmology.